Introduction: Chronic Medical Conditions and Depression-the View from Primary Care

American Journal of Medicine

Volumn 121, Issue 11 SUPPL. 2, 2008, Pages

  Kravitz, Richard L ^a   Ford, Daniel E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; CITALOPRAM; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; LITHIUM; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHENOTHIAZINE; PHENYTOIN; PROPAFENONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLBUTAMIDE; TRAMADOL; TRIPTAN DERIVATIVE; VENLAFAXINE; WARFARIN;

ARTHRITIS; BEHAVIOR THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; EDITORIAL; HUMAN; LONG TERM CARE; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; RISK FACTOR; SEIZURE; SEROTONIN SYNDROME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNITED STATES;

ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; COMORBIDITY; DEPRESSION; DRUG INTERACTIONS; HUMANS; PRIMARY HEALTH CARE; SELF EFFICACY;

EID: 54049099629     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.08.003     Document Type: Editorial

References (56)

1. Family physicians and the primary care physicians workforce in 2004. [Graham Center One-Pager). Am Fam Phys. 71 (2005) 2260
2. Bodenheimer T. Primary care-will it survive?. N Engl J Med. 355 (2006) 861-864
3. Grumbach K. Primary care in the United States-the best of times, the worst of times. N Engl J Med. 341 (1999) 2008-2010
4. Larson E.B., Grumbach K., and Roberts K.B. The future of generalism in medicine. Ann Intern Med. 142 (2005) 689-690
5. Green L.A., Hames Sr. C.G., and Nutting P.A. Potential of practice-based research networks: experiences from ASPN. [Ambulatory Sentinel Practice Network]. J Fam Pract. 38 (1994) 400-406
6. Hoffman C., Rice D., and Sung H.Y. Persons with chronic conditions: their prevalence and costs. JAMA 276 (1996) 1473-1479
7. Woolf S.H., and Johnson R.E. The break-even point: when medical advances are less important than improving the fidelity with which they are delivered. Ann Fam Med. 3 (2005) 545-552
8. Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., and Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370 (2007) 851-858
9. Katon W.J. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 54 (2003) 216-226
10. Eaton W.W., Armenian H., Gallo J., Pratt L., and Ford D.E. Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care 19 (1996) 1097-1102
11. Kawakami N., Takatsuka N., Shimizu H., and Ishibashi H. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 22 (1999) 1071-1076
12. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med. 23 (2002) 51-61
13. Sobel R.M., Lotkowski S., and Mandel S. Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis. Curr Psychiatry Rep. 7 (2005) 396-403
14. Moxey E., O'Connor J., Novielli K., Teutsch S., and Nash D. Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev. 24 (2003) 127-141
15. Celexa. [package insert] (2007), Forest Pharmaceuticals, Inc, St. Louis, MO
16. Cymbalta. [package insert] (2007), Eli Lilly and Company, Indianapolis, IN
17. Effexor XR. [package insert] (2008), Wyeth Pharmaceuticals Inc, Philadelphia, PA
18. Fluvoxamine maleate tablets. [package insert] (2000), Purepac Pharmaceutical Co, Elizabeth, NJ
19. Lexapro. [package insert] (2007), Forest Pharmaceuticals, Inc, St. Louis, MO
20. Prozac. [package insert] (2008), Eli Lilly and Company, Indianapolis, IN
21. Paxil. [package insert] (2008), GlaxoSmithKline, Research Triangle Park, NC
22. Wellbutrin XL. [package insert] (2007), GlaxoSmithKline, Research Triangle Park, NC
23. Zoloft. [package insert] (2008), Pfizer Inc, New York, NY
24. Schatzberg A.F. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 68 suppl 8 (2007) 26-34
25. Davidson K.W., Kupfer D.J., Bigger J.T., et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Ann Behav Med. 32 (2006) 121-126
26. McDonald W.M., Richard I.H., and DeLong M.R. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54 (2003) 363-375
27. Williams M.M., Clouse R.E., and Lustman P.J. Treating depression to prevent diabetes: understanding depression as a medical complication. Clin Diabetes 24 (2006) 79-86
28. Lustman P.J., Griffith L.S., Clouse R.E., et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med. 59 (1997) 241-250
29. Starkstein S.E., Mizrahi R., and Power B.D. Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother. 9 (2008) 1291-1298
30. Sheline Y.I., Freedland K.E., and Carney R.M. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?. Am J Med. 102 (1997) 54-59
31. Robinson R., Jorge R., Moser D., et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA 299 (2008) 2391-2400
32. Lesperance F., Frasure-Smith N., Koszycki D., et al., CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 297 (2007) 367-379
33. Breum L., Bjerre U., Bak J.F., Jacobsen S., and Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 44 (1995) 1570-1576
34. Lustman P.J., Freedland K.E., Griffith L.S., and Clouse R.E. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23 (2000) 618-623
35. Strik J.J., Honig A., Lousberg R., et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 62 (2000) 783-789
36. Lustman P.J., Clouse R.E., Nix B.D., et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 63 (2006) 521-529
37. Glassman A.H., O'Connor C.M., Califf R.M., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288 (2002) 701-709
38. Lustman P.J., Williams M.M., Sayuk G.S., Nix B.D., and Clouse R.E. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 30 (2007) 459-466
39. Duby J.J., Campbell R.K., Setter S.M., White J.R., and Rasmussen K.A. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 61 (2004) 160-173 quiz 175-176
40. Jann M.W., and Slade J.H. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 27 (2007) 1571-1587
41. Lustman P.J., Griffith L.S., Freedland K.E., Kissel S.S., and Clouse R.E. Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 129 (1998) 613-621
42. Johnson E.M., Whyte E., Mulsant B.H., et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 14 (2006) 796-802
43. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, Text Revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
44. Sayar K., Kirmayer L.J., and Taillefer S.S. Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry 25 (2003) 108-114
45. Mold J.W., and Stein H.F. The cascade effect in the clinical care of patients. N Engl J Med. 314 (1986) 512-514
46. Himelhoch S., Weller W.E., Wu A.W., Anderson G.F., and Cooper L.A. Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med Care 42 (2004) 512-521
47. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 84 (1977) 191-215
48. Hays R., Cunningham W., Ettl M., Beck C., and Shapiro M. Health-related quality of life in HIV disease. Assessment 2 (1995) 363-380
49. Wagner E.H., Austin B.T., and Von Korff M. Organizing care for patients with chronic illness. Milbank Q 74 (1996) 511-544
50. Bodenheimer T., Wagner E.H., and Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA 288 (2002) 1909-1914
51. Bodenheimer T., Wagner E.H., and Grumbach K. Improving primary care for patients with chronic illness. JAMA 288 (2002) 1775-1779
52. Tsai A.C., Morton S.C., Mangione C.M., and Keeler E.B. A meta-analysis of interventions to improve care for chronic illnesses. Am J Manag Care 11 (2005) 478-488
53. Burt C.W., and Sisk J.E. Which physicians and practices are using electronic medical records?. Health Aff (Millwood) 24 (2005) 1334-1343
54. Dorr D.A., Wilcox A., Burns L., Brunker C.P., Narus S.P., and Clayton P.D. Implementing a multidisease chronic care model in primary care using people and technology. Dis Manag. 9 (2006) 1-15
55. Kroenke K., Spitzer R.L., and Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 16 (2001) 606-613
56. Trivedi M.H., Lin E.H., and Katon W.J. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 12 suppl 13 (2007) 1-27